GAMMA Investing LLC Has $45,000 Position in Genmab A/S (NASDAQ:GMAB)

GAMMA Investing LLC boosted its stake in shares of Genmab A/S (NASDAQ:GMAB) by 96.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,139 shares of the company’s stock after acquiring an additional 1,051 shares during the quarter. GAMMA Investing LLC’s holdings in Genmab A/S were worth $45,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Blue Trust Inc. raised its stake in Genmab A/S by 892.0% during the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after acquiring an additional 3,880 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Genmab A/S by 43.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock worth $113,000 after acquiring an additional 1,413 shares in the last quarter. Headlands Technologies LLC raised its stake in Genmab A/S by 1,702.8% during the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after acquiring an additional 4,853 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after acquiring an additional 478 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC acquired a new position in Genmab A/S during the third quarter worth $192,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Down 1.9 %

Genmab A/S stock opened at $21.72 on Tuesday. The business’s 50-day simple moving average is $21.29 and its 200 day simple moving average is $24.17. The stock has a market cap of $14.37 billion, a price-to-earnings ratio of 21.09, a P/E/G ratio of 0.63 and a beta of 0.97. Genmab A/S has a 12-month low of $19.85 and a 12-month high of $31.88.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same quarter in the prior year, the business earned $0.47 EPS. As a group, sell-side analysts expect that Genmab A/S will post 1.28 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on GMAB. BMO Capital Markets reiterated an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Wednesday, January 8th. Finally, Redburn Atlantic assumed coverage on Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.